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Atrial (ANP) and B-type natriuretic peptides (BNP) are cardiac hormones released by the 
heart in response to myocardial stretch and volume overload (1). ANP and BNP induce 
vasodilation, natriuresis and suppress the renin-angiotensin-aldosterone system. In heart 
failure (HF), ANP and BNP are highly produced and secreted from the atria and ventricles 
in the attempt to compensate the increased cardiac filling pressures. Natriuretic peptides 
exert also a metabolic action, indeed, ANP and BNP induce lipolysis in vitro and vivo (2). In 
consideration of the metabolic properties of natriuretic peptides, it is still debated whether 
these hormones play a role in weight loss observed in cardiac cachexia. Previous studies 
conducted in general populations from Massachusetts, Sweden, Finland, Minnesota and Italy 
reported that the ANP genetic variant rs5068 is associated with higher circulating levels of 
ANP, BNP and lower blood pressure values, body mass index (BMI), waist circumference, 
prevalence of hypertension, obesity and metabolic syndrome (3-5). To date no studies have 
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described the phenotype related to rs5068 in the clinical context of chronic heart failure. 
Hence, the aim of our study was to characterize in-depth the cardiovascular and metabolic 
phenotype associated with rs5068 in a cohort of heart failure patients.
We genotyped a subset of 1173 HF patients (with available blood samples) from the GISSI 
Heart Failure (GISSI-HF) study cohort (6). The study has been approved by the Ethic 
Committees of the hospitals participating in the GISSI-HF study and conforms to the 
principles outlined in the Declaration of Helsinki. All subjects gave written informed 
consent to participate in the study. Continuous variables were compared by rs5068 genotype 
(AG vs AA) by analysis of variance (ANOVA) or Wilcoxon rank test as appropriate, as well 
as categorical variables were compared by logistic regression. Skewed variables were 
transformed to approximate normality with the logarithmic transformation. The association 
of the genotype with the study outcomes was assessed by multivariable Cox proportional 
hazards model.
Genotype frequencies of rs5068 were 94% (n= 1098) for AA and 6% (n= 75) for AG 
corresponding to a minor allele frequency of 3% (table 1). All comparisons are AG vs AA. 
In a multivariable analysis adjusted for age, sex, BMI, serum creatinine and New York Heart 
Association (NYHA) class, the G allele was associated with higher plasma concentrations of 
mid-regional pro-ANP (MR-proANP) (median 235 vs 206 pmol/L, p= 0.048) and BNP (180 
vs 141 pg/ml, p= 0.027) (figure 1). Carriers of the minor allele tended to have higher NT-
proBNP plasma levels (1161 vs 837 pg/ml, p= 0.13). At the age and sex adjusted analysis 
the two groups did not differ in terms of systolic (126.8 vs 125.2 mmHg, p= 0.53), diastolic 
(76.2 vs 76.5 mmHg, p= 0.85) blood pressures, prevalence of hypertension (61.3% vs 
55.3%, p = 0.35) and BMI (26.5 vs 27.0 kg/m2, p= 0.43) (tables 1). The prevalence of 
weight loss ≥ 5% in one year was similar between groups in the regression model adjusted 
for NYHA class, atrial fibrillation, age, heart rate, total cholesterol, glomerular filtration 
rate, central venous pressure, previous hospitalization, ascites, hepatomegaly, pulmonary 
congestion, peripheral edema (OR: 0.73 [95% CI 0.36-1.52], p = 0.40). In the 4-year follow-
up, incidence of all-cause mortality (30.7% vs 26.7%, p= 0.37), cardiovascular mortality 
(25.3% vs 19.5%, p = 0.18) and hospitalization for cardiovascular reasons (60% vs 56.4%, 
p= 0.76) were not different between genotypes. In the multivariable analysis adjusted for 
age, sex, NYHA class, atrial fibrillation, diabetes mellitus, chronic obstructive pulmonary 
disease, diastolic blood pressure, LV ejection fraction, serum levels of total cholesterol, 
creatinine and triglycerides, third heart sound, uricemia and therapy with diuretics or beta-
blockers, the G allele was not associated with risk of all-cause mortality (HR: 0.94 [95% CI 
0.6 – 1.46], p=0.78), cardiovascular mortality (HR: 1.03 [95% CI 0.6 – 1.69], p=0.89) or 
hospitalization for cardiovascular reasons (HR: 1.07 [95% CI 0.79 – 1.46], p=0.65) during a 
4-year follow up.
Consistent with previous studies conducted in general populations (3-5), HF patients who 
are carriers of rs5068 minor allele have significantly higher circulating levels of MR-
proANP, which is a reliable estimator of ANP secretion, and BNP. Levels of NT-proBNP 
tend to be higher in the AG genotype. Regarding the mechanism that might cause the 
increase in circulating ANP levels in the carriers of rs5068 minor allele, an elegant recent 
study showed that the presence of the G allele counteracts the regulatory action of 
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microRNA miR-425, which inhibits NPPA expression (7). By preventing binding of 
miR-425 to NPPA gene, rs5068 G allele results in increased expression of the ANP gene and 
higher circulating levels of ANP. Whether the interaction between miR-425 and rs5068 
might also cause higher circulating levels of BNP and NT-proBNP is still unknown but 
more likely, rs5068 could be in linkage disequilibrium with another single nucleotide 
polymorphism that is associated with higher BNP and NT-proBNP plasma values.
In our study, systolic and diastolic blood pressure, BMI and prevalence of hypertension did 
not differ according to rs5068 genotypes. In consideration of the metabolic properties of 
NPs we also analyzed whether rs5068 could be associated with a decrease in body weight ≥ 
5% in one year, which is one of the main features for the diagnosis of cachexia (8), and no 
relation was found. A possible explanation could be related to the altered molecular forms of 
natriuretic peptides (NPs) that are produced in HF and might have impaired cardiovascular 
as well as metabolic properties (9,10). Further, in the metabolic dysfunction of heart failure 
the role played by inflammatory cytokines, hormones and neurotransmitters might minimize 
the possible metabolic effect exerted by NPs in general and more specifically by the increase 
in circulating NPs associated with rs5068.
In our 4 year follow-up analysis, the genetic variant rs5068 is not associated with all-cause 
mortality, cardiovascular mortality and hospitalization for cardiovascular reason. The 
biological effect of the increased circulating levels of NPs associated with rs5068 minor 
allele are likely overcome by major components such as therapy, compliance to therapy and 
comorbidities that have a stronger clinical impact in the final outcome of chronic heart 
failure.
Further investigations in larger cohorts may be required to evaluate whether rs5068 has an 
influence on clinical outcomes in HF patients.
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Figure 1. Natriuretic Peptides Plasma Levels according to rs5068 Genotypes
* P values obtained from analysis of variance on log transformed data, adjusted for age, sex, 
New York heart association class, body mass index and creatinine. Horizontal lines in the 
graphs represent first quartile, median and third quartile. Mid-regional pro-atrial natriuretic 
peptide (MR-proANP), B-type natriuretic peptide (BNP), N-terminal-proBNP (NT-proBNP)
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